C3 gets the job done, but it has flaws. It fails and uses the wrong molecule about 20% of the time, whereas C4 eliminates this inefficiency and the need to break down the incorrect molecule afterward.

A genotype match thought to be associated with favorable outcomes after deceased-donor kidney transplantation offers no advantage over other genotype pairings, Mira Varagunam and colleagues report.

This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal ...